bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2022-67-1-108-120bloodjour-340Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREМетодические аспекты детекции минимальной остаточной болезни у больных острыми лейкозамиMethodological aspects of the detection of minimal residual disease in patients with acute leukemiahttps://orcid.org/0000-0002-8490-6066ГальцеваИ. В.GaltsevaI. V.

Гальцева Ирина Владимировна, кандидат медицинских наук, заведующая научно-клинической лабораторией иммунофенотипирования клеток крови и костного мозга 

125167, Москва

Irina V. Galtseva, Cand. Sci. (Med.), Head of the Laboratory for Immunophenotyping of Blood and Bone Marrow Cells 

125167, Moscow

irinagaltseva@gmail.comhttps://orcid.org/0000-0001-6220-8868СмирноваС. Ю.SmirnovaS. Y.

Смирнова Светлана Юрьевна, кандидат медицинских наук, научный сотрудник лаборатории молекулярной гематологии 

125167, Москва

Svetlana Y. Smirnova, Cand. Sci. (Med.), Researcher, Laboratory of Molecular Hematology 

125167, Moscow

smirnova-s-ju@yandex.ruhttps://orcid.org/0000-0001-6177-3566ПаровичниковаЕ. Н.ParovichnikovaE. N.

Паровичникова Елена Николаевна, доктор медицинских наук, генеральный директор 

125167, Москва

Elena N. Parovichnikova, Dr. Sci. (Med.), CEO of the National Research Center for Hematology 

125167, Moscow

parovichnikova.e@blood.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for HematologyRussian Federation202211042022671108120Copyright © Гальцева И.В., Смирнова С.Ю., Паровичникова Е.Н., 20222022Гальцева И.В., Смирнова С.Ю., Паровичникова Е.Н.Galtseva I.V., Smirnova S.Y., Parovichnikova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/340Введение

Введение. Исследование минимальной остаточной болезни (МОБ) является необходимым при выполнении многих протоколов терапии острых лейкозов. Для оценки МОБ применяются методы полимеразной цепной реакции (ПЦР) и многоцветной проточной цитометрии (МПЦ).

Цель — охарактеризовать основные технологии обнаружения остаточных опухолевых клеток при острых лейкозах.

Основные сведения

Основные сведения. Описываются различные подходы к обнаружению МОБ: ПЦР с пациент-специфическими праймерами для реаранжировок генов иммуноглобулина и/или Т-клеточных рецепторов, ПЦР с обратной транскрипцией для обнаружения химерных транскриптов и оценки экспрессии гиперэкспрессированных генов, а также основы детекции МОБ методом МПЦ. Обсуждаются достоинства, недостатки и ограничения различных методов определения МОБ.

Introduction

Introduction. The study of minimal residual disease (MRD) has become an integral part of various treatment protocols for acute leukemia. Methods of polymerase chain reaction (PCR) and multicolor fl ow cytometry (MFC) are most widely used to assess MRD.

Aim — to characterize the main technologies for the detection of residual tumor cells in acute leukemia

Main findings

Main findings. Various approaches for detecting MRD are described: PCR with patient-specifi c primers for rearranged genes of immunoglobulin and/or T-cell receptors, reverse transcription PCR for detecting chimeric transcripts and assessing the expression of overexpressed genes, as well as the basics of detecting MRD by MFC. Each of these approaches has its own advantages, disadvantages, and limitations of use.

минимальная остаточная болезньмногоцветная проточная цитометрияполимеразная цепная реакцияострые лимфобластные лейкозыострые миелоидные лейкозыminimal residual diseasemulticolor fl ow cytometrypolymerase chain reactionacute lymphoblastic leukemiaacute myeloid leukemiaReferencesГальцева И.В., Давыдова Ю.О., Паровичникова Е.Н. Определение минимальной измеримой остаточной болезни у взрослых больных острыми лейкозами. Гематология и трансфузиология. 2020; 65(4): 460–72. DOI: 10.35754/0234-5730-2020-65-4-460-472.Galtseva I.V., Davydova Y.O., Parovichnikova E.N. Detection of measurable residual disease in adults with acute leukaemia. Gematologiya i transfuziologiya. 2020; 65(4): 460–72. DOI: 10.35754/0234-5730-2020-65-4-460-472. (In Russian).van Dongen J.J.M., van der Velden V.H.J., Brüggemann M., Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies. Blood. 2015; 125(26): 3996–4009. DOI: 10.1182/blood-2015-03-580027.van Dongen J.J.M., van der Velden V.H.J., Brüggemann M., Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies. Blood. 2015; 125(26): 3996–4009. DOI: 10.1182/blood-2015-03-580027.Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010: 7–12. DOI: 10.1182/asheducation-2010.1.7.Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010: 7–12. DOI: 10.1182/asheducation-2010.1.7.Szczepański T., van der Velden V.H.J., Raff T., et al. Comparative analysis of Tcell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL. Leukemia. 2003; 17(11): 2149–56. DOI: 10.1038/sj.leu.2403081.Szczepański T., van der Velden V.H.J., Raff T., et al. Comparative analysis of Tcell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL. Leukemia. 2003; 17(11): 2149–56. DOI: 10.1038/sj.leu.2403081.van Dongen J.J.M., Langerak A.W., Brüggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12): 2257–317. DOI: 10.1038/sj.leu.2403202.van Dongen J.J.M., Langerak A.W., Brüggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12): 2257–317. DOI: 10.1038/sj.leu.2403202.van der Velden V.H.J., Cazzaniga G., Schrauder A., et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for inter-pretation of real-time quantitative PCR data. Leukemia. 2007; 21(4): 604–11. DOI: 10.1038/sj.leu.2404586.van der Velden V.H.J., Cazzaniga G., Schrauder A., et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for inter-pretation of real-time quantitative PCR data. Leukemia. 2007; 21(4): 604–11. DOI: 10.1038/sj.leu.2404586.Смирнова С.Ю., Сидорова Ю.В., Судариков А.Б. Методика определения минимальной остаточной болезни при остром лимфобластном лейкозе. Справочник заведующего КДЛ. 2015; 4: 50–61.Smirnova S.Yu., Sidorova Yu.V., Sudarikov A.B. Method for determining the minimal residual disease in acute lymphoblastic leukemia. Spravochnik zaveduyushchego KDL. 2015; 4: 50–61. (In Russian).Multicenter clinical trial for adult Ph-negative ALL. Non-intensive but noninterruptive treatment. ClinicalTrials.gov (database of privately and publicly funded clinical studies). 2010. URL: https://clinicaltrials.gov/Multicenter clinical trial for adult Ph-negative ALL. Non-intensive but noninterruptive treatment. ClinicalTrials.gov (database of privately and publicly funded clinical studies). 2010. URL: https://clinicaltrials.gov/Смирнова С.Ю., Сидорова Ю.В., Рыжикова Н.В. и др. Эволюция опухолевых клонов при остром лимфобластном лейкозе взрослых. Acta naturae (русскоязычная версия). 2016; 8(4): 108–18.Smirnova S.Yu., Sidorova Yu.V., Ryzhikova N.V., et al. Evolution of tumor clones in acute lymphoblastic leukemia in adults. Acta naturae. 2016; 8(4): 108–18. (In Russian).van Dongen J.J., Macintyre E.A., Gabert J.A., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13(12): 1901–28. DOI: 10.1038/sj.leu.2401592.van Dongen J.J., Macintyre E.A., Gabert J.A., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13(12): 1901–28. DOI: 10.1038/sj.leu.2401592.Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol. 2003; 121(6): 823–38. DOI: 10.1046/j.1365-2141.2003.04393.x.Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol. 2003; 121(6): 823–38. DOI: 10.1046/j.1365-2141.2003.04393.x.Scholl C., Breitinger H., Schlenk R.F., et al. Development of a real-time RT-PCR assay for the quantifi cation of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes Chromosomes Cancer. 2003; 38(3): 274–80. DOI: 10.1002/gcc.10284.Scholl C., Breitinger H., Schlenk R.F., et al. Development of a real-time RT-PCR assay for the quantifi cation of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes Chromosomes Cancer. 2003; 38(3): 274–80. DOI: 10.1002/gcc.10284.Gabert J., Beillard E., van der Velden V.H.J., et al. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia — A Europe Against Cancer program. Leukemia. 2003; 17(12): 2318–57. DOI: 10.1038/sj.leu.2403135.Gabert J., Beillard E., van der Velden V.H.J., et al. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia — A Europe Against Cancer program. Leukemia. 2003; 17(12): 2318–57. DOI: 10.1038/sj.leu.2403135.Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. В 2 т. Т. 1. М.: Практика; 2018.Diagnostic algorithms and protocols for the treatment of diseases of the blood system. Ed. V.G. Savchenko. Vol. 1. Moscow: Praktika; 2018. (In Russian).Döhner H., Estey E., Grimwade D., et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4): 424–47. DOI: 10.1182/blood-2016-08-733196.Döhner H., Estey E., Grimwade D., et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4): 424–47. DOI: 10.1182/blood-2016-08-733196.Chen Z., Tong Y., Li Y., et al. Development and validation of a 3-Plex RT-qPCR assay for the simultaneous detection and quantitation of the three PML-RARa fusion transcripts in acute promyelocytic leukemia. PLoS One. 2015; 10(3): e0122530. DOI: 10.1371/journal.pone.0122530.Chen Z., Tong Y., Li Y., et al. Development and validation of a 3-Plex RT-qPCR assay for the simultaneous detection and quantitation of the three PML-RARa fusion transcripts in acute promyelocytic leukemia. PLoS One. 2015; 10(3): e0122530. DOI: 10.1371/journal.pone.0122530.Grimwade D., Hills R.K., Moorman A.V., et al. Refi nement of cytogenetic classifi cation in acute myeloid leukemia: determination of prognostic signifi cance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354–65. DOI: 10.1182/blood-2009-11-254441.Grimwade D., Hills R.K., Moorman A.V., et al. Refi nement of cytogenetic classifi cation in acute myeloid leukemia: determination of prognostic signifi cance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354–65. DOI: 10.1182/blood-2009-11-254441.Ouyang J., Goswami M., Peng J., et al. Comparison of multiparameter fl ow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia. Am J Clin Pathol. 2016; 145(6): 769–77. DOI: 10.1093/ajcp/aqw038.Ouyang J., Goswami M., Peng J., et al. Comparison of multiparameter flow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia. Am J Clin Pathol. 2016; 145(6): 769–77. DOI: 10.1093/ajcp/aqw038.Gilliland D.G., Griffi n J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002; 100(5): 1532–42. DOI: 10.1182/blood-2002-02-0492.Gilliland D.G., Griffi n J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002; 100(5): 1532–42. DOI: 10.1182/blood-2002-02-0492.Papaemmanuil E., Gerstung M., Bullinger L., et al. Genomic classifi cation and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23): 2209–21. DOI: 10.1056/NEJMoa1516192.Papaemmanuil E., Gerstung M., Bullinger L., et al. Genomic classifi cation and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23): 2209–21. DOI: 10.1056/NEJMoa1516192.Kottaridis P.D., Gale R.E., Langabeer S.E., et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002; 100(7): 2393–8. DOI: 10.1182/blood-2002-02-0420.Kottaridis P.D., Gale R.E., Langabeer S.E., et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002; 100(7): 2393–8. DOI: 10.1182/blood-2002-02-0420.Lindström M.S. NPM1/B23: A multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int. 2011; 2011: 195209. DOI: 10.1155/2011/195209.Lindström M.S. NPM1/B23: A multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int. 2011; 2011: 195209. DOI: 10.1155/2011/195209.Schnittger S., Kern W., Tschulik C., et al. Minimal residual disease levels assessed by NPM1 mutation-specifi c RQ-PCR provide important prognostic information in AML. Blood. 2009; 114(11): 2220–31. DOI: 10.1182/blood-2009-03-213389.Schnittger S., Kern W., Tschulik C., et al. Minimal residual disease levels assessed by NPM1 mutation-specifi c RQ-PCR provide important prognostic information in AML. Blood. 2009; 114(11): 2220–31. DOI: 10.1182/blood-2009-03-213389.Hirsch P., Tang R., Marzac C., et al. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC. Haematologica. 2012; 97(2): 241–5. DOI: 10.3324/haematol.2010.034447.Hirsch P., Tang R., Marzac C., et al. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC. Haematologica. 2012; 97(2): 241–5. DOI: 10.3324/haematol.2010.034447.Lugthart S., van Drunen E., van Norden Y., et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008; 111(8): 4329–37. DOI: 10.1182/blood-2007-10-119230.Lugthart S., van Drunen E., van Norden Y., et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008; 111(8): 4329–37. DOI: 10.1182/blood-2007-10-119230.Hämäläinen M.M., Kairisto V., Juvonen V., et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol. 2008; 80(3): 201–7. DOI: 10.1111/j.1600-0609.2007.01009.x.Hämäläinen M.M., Kairisto V., Juvonen V., et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol. 2008; 80(3): 201–7. DOI: 10.1111/j.1600-0609.2007.01009.x.Мамаев Н.Н., Горбунов А.В., Бархатов И.М. и др. Молекулярный мониторинг течения острых миелоидных лейкозов по уровню экспрессии гена WT1 после аллогенной трансплантации гемопоэтических стволовых клеток. Клиническая онкогематология. 2015; 8(3): 309–20.Mamaev N.N., Gorbunov A.V., Barkhatov I.M., et al. Molecular monitoring of WT1 gene expression in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Clinical oncohematology. 2015; 8(3): 309–20. (In Russian).Schuurhuis G.J., Heuser M., Freeman S., et al. Minimal/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12): 1275–91. DOI: 10.1182/blood-2017-09-801498.Schuurhuis G.J., Heuser M., Freeman S., et al. Minimal/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12): 1275–91. DOI: 10.1182/blood-2017-09-801498.Nunes V., Cazzaniga G., Biondi A. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Expert Rev Mol Diagn. 2017; 17(11): 953–63. DOI: 10.1080/14737159.2017.1377073.Nunes V., Cazzaniga G., Biondi A. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Expert Rev Mol Diagn. 2017; 17(11): 953–63. DOI: 10.1080/14737159.2017.1377073.Попов А.М., Вержбицкая Т.Ю., Фечина Л.Г. и др. Острые лейкозы: различия иммунофенотипа бластных клеток и их неопухолевых аналогов в костном мозге. Клиническая онкогематология. 2016; 9(3): 302–13.Popov A.M., Verzhbitskaya T.Yu., Fechina L.G., et al. Acute leukemia: differences in the immunophenotype of blast cells and their non-tumor analogues in the bone marrow. Klinicheskaya onkogematologiya. 2016; 9(3): 302–13. (In Russian).Wood B.L. Principles of minimal residual disease detection for hematopoietic neoplasms by fl ow cytometry. Cytometry B Clin Cytom. 2016; 90(1): 47–53. DOI: 10.1002/cyto.b.21239.Wood B.L. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016; 90(1): 47–53. DOI: 10.1002/cyto.b.21239.Wood B.L. Multicolor immunophenotyping: Human immune system hematopoiesis. Methods Cell Biol. 2004; 75: 559–76. DOI: 10.1016/s0091-679x(04)75023-2.Wood B.L. Multicolor immunophenotyping: Human immune system hematopoiesis. Methods Cell Biol. 2004; 75: 559–76. DOI: 10.1016/s0091-679x(04)75023-2.Wood B.L. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol. 2013; 999: 123–36. DOI: 10.1007/978-1-62703-357-2_8.Wood B.L. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol. 2013; 999: 123–36. DOI: 10.1007/978-1-62703-357-2_8.Rimsza L.M., Larson R.S., Winter S.S., et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol. 2000; 114(1): 66–75. DOI: 10.1309/LXU4-Q7Q9-3YAB-4QE0.Rimsza L.M., Larson R.S., Winter S.S., et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol. 2000; 114(1): 66–75. DOI: 10.1309/LXU4-Q7Q9-3YAB-4QE0.Wohlfahrt A.B., Hannel L., Oliveira L.Z., et al. The importance of immunophenotyping by fl ow cytometry in distinction between hematogones and B lymphoblasts. J Bras Patol e Med Lab. 2015; 51(1): 7–12. DOI: 10.5935/1676-2444.20150002.Wohlfahrt A.B., Hannel L., Oliveira L.Z., et al. The importance of immunophenotyping by flow cytometry in distinction between hematogones and B lymphoblasts. J Bras Patol e Med Lab. 2015; 51(1): 7–12. DOI: 10.5935/1676-2444.20150002.Ciudad J., Orfao A., Vidriales B., et al. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection. Haematologica. 1998; 83(12): 1069–75.Ciudad J., Orfao A., Vidriales B., et al. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection. Haematologica. 1998; 83(12): 1069–75.Borowitz M.J., Pullen D.J., Shuster J.J., et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. Leukemia. 2003; 17(8): 1566–72. DOI: 10.1038/sj.leu.2403001.Borowitz M.J., Pullen D.J., Shuster J.J., et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. Leukemia. 2003; 17(8): 1566–72. DOI: 10.1038/sj.leu.2403001.Muzzafar T., Medeiros L.J., Wang S.A., et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by fl ow cytometry. Am J Clin Pathol. 2009; 132(5): 692–8. DOI: 10.1309/AJCP02RPVOKTNWEC.Muzzafar T., Medeiros L.J., Wang S.A., et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol. 2009; 132(5): 692–8. DOI: 10.1309/AJCP02RPVOKTNWEC.Campana D., Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002; 15(1): 1–19. DOI: 10.1053/beha.2002.0182.Campana D., Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002; 15(1): 1–19. DOI: 10.1053/beha.2002.0182.Porwit-MacDonald A., Björklund E., Lucio P., et al. BIOMED-1 concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2000; 14(5): 816–25. DOI: 10.1038/sj.leu.2401741.Porwit-MacDonald A., Björklund E., Lucio P., et al. BIOMED-1 concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2000; 14(5): 816–25. DOI: 10.1038/sj.leu.2401741.Лобанова Т.И., Гальцева И.В., Паровичникова Е.Н. Исследование минимальной остаточной болезни у пациентов с острыми миелоидными лейкозами методом многоцветной проточной цитофлуориметрии (обзор литературы). Онкогематология. 2018; 13(1): 83–102. DOI: 10.17650/1818-8346-2018-13-1-83-102.Lobanova T.I., Galtseva I.V., Parovichnikova E.N. Minimal residual disease assessment in patients with acute myeloid leukemia by multicolour flow cytometry (literature review). Onkogematologiya. 2018; 13(1): 83–102. DOI: 10.17650/1818-8346-2018-13-1-83-102. (In Russian).Tien H.F, Wang C.H. CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma. 1998; 31(1-2): 93–8. DOI: 10.3109/10428199809057588.Tien H.F, Wang C.H. CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma. 1998; 31(1-2): 93–8. DOI: 10.3109/10428199809057588.Jorgensen J.L., Chen S.S. Monitoring of minimal residual disease in acute myeloid leukemia: Methods and best applications. Clin Lymphoma Myeloma Leuk. 2011; 11 Suppl 1: S49–53. DOI: 10.1016/j.clml.2011.03.023.Jorgensen J.L., Chen S.S. Monitoring of minimal residual disease in acute myeloid leukemia: Methods and best applications. Clin Lymphoma Myeloma Leuk. 2011; 11 Suppl 1: S49–53. DOI: 10.1016/j.clml.2011.03.023.Jaso J.M., Wang S.A., Jorgensen J.L., Lin P. Multi-color fl ow cytometric immunophenotyping for detection of minimal residual disease in AML: Past, present and future. Bone Marrow Transplant. 2014; 49(9): 1129–38. DOI: 10.1038/bmt.2014.99.Jaso J.M., Wang S.A., Jorgensen J.L., Lin P. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: Past, present and future. Bone Marrow Transplant. 2014; 49(9): 1129–38. DOI: 10.1038/bmt.2014.99.Langebrake C., Brinkmann I., Teigler-Schlegel A., et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom. 2005; 63(1): 1–9. DOI: 10.1002/cyto.b.20037.Langebrake C., Brinkmann I., Teigler-Schlegel A., et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom. 2005; 63(1): 1–9. DOI: 10.1002/cyto.b.20037.Cui W., Zhang D., Cunningham M.T., Tilzer L. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: Changes at refractory disease or fi rst relapse and clinicopathological fi ndings. Int J Lab Hematol. 2014; 36(6): 636–49. DOI: 10.1111/ijlh.12193.Cui W., Zhang D., Cunningham M.T., Tilzer L. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: Changes at refractory disease or fi rst relapse and clinicopathological fi ndings. Int J Lab Hematol. 2014; 36(6): 636–49. DOI: 10.1111/ijlh.12193.Baer M.R., Stewart C.C., Dodge R.K., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001; 97(11): 3574–80. DOI: 10.1182/blood.v97.11.3574.Baer M.R., Stewart C.C., Dodge R.K., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001; 97(11): 3574–80. DOI: 10.1182/blood.v97.11.3574.Voskova D., Schoch C., Schnittger S., et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic fi ndings. Cytometry. 2004; 62(1): 25–38. DOI: 10.1002/cyto.b.20025.Voskova D., Schoch C., Schnittger S., et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic fi ndings. Cytometry. 2004; 62(1): 25–38. DOI: 10.1002/cyto.b.20025.Grimwade D., Freeman S.D. Defi ning minimal residual disease in acute myeloid leukemia: Which platforms are ready for “prime time”? Hematology Am Soc Hematol Educ Program. 2014; 2014(1): 222–33. DOI: 10.1182/asheducation-2014.1.222.Grimwade D., Freeman S.D. Defi ning minimal residual disease in acute myeloid leukemia: Which platforms are ready for “prime time”? Hematology Am Soc Hematol Educ Program. 2014; 2014(1): 222–33. DOI: 10.1182/asheducation-2014.1.222.Stetler-Stevenson M., Paiva B., Stoolman L., et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytom Part B Clin Cytom. 2016; 90(1): 26–30. DOI: 10.1002/cyto.b.21249.Stetler-Stevenson M., Paiva B., Stoolman L., et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytom Part B Clin Cytom. 2016; 90(1): 26–30. DOI: 10.1002/cyto.b.21249.

The authors declare that there are no conflicts of interest present.